

Application No.: 10/717,290

Amendments to the Claims:


Please cancel Claims 1-23. Please add Claims 24-46.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing:

1-23. (Cancelled)

24. (New) A compound represented by formula:



and pharmaceutically acceptable salts, esters, prodrugs, racemic mixtures and stereoisomers thereof.


25. (New) A compound according to claim 24 wherein the compound is a pharmaceutically acceptable salt.

26. (New) A compound according to claim 24 wherein the compound is a free base.

27. (New) A compound according to claim 24 wherein the compound is an ester or prodrug.

Application No.: 10/717,290

28. (New) A compound according to claim 24 wherein the compound is an E oxime isomer.
29. (New) A compound according to claim 24 wherein the compound is a Z oxime isomer.
30. (New) A method for treating an infection or a disorder related to an infection in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of a compound according to the formula:



and pharmaceutically acceptable salts, esters, prodrugs, racemic mixtures and stereoisomers thereof.

31. (New) A method according to claim 30 wherein the compound is pharmaceutically acceptable salt.
32. (New) A method according to claim 30 wherein the compound is a free base.
33. (New) A method according to claim 30 wherein the compound is an ester or prodrug.

Application No.: 10/717,290

34. (New) A method according to claim 30 wherein the compound is an E oxime isomer.
35. (New) A method according to claim 30 wherein the compound is a Z oxime isomer.
36. (New) The method according to claim 30 wherein the compound is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
37. (New) The method according to claim 30 wherein the compound is administered orally or by injection.
38. (New) The method according to claim 30 wherein the subject is a human.
39. (New) The method according to claim 30 wherein the compound is administered in combination with one or more antibiotics.
40. (New) The method according to claim 39 wherein the antibiotic is selected from the group consisting of penicillin, amoxicillin, azithromycin, erythromycin, ciprofloxacin, telithromycin, and cethromycin or a pharmaceutically acceptable salt, ester, or prodrug thereof.
41. (New) The method according to Claim 30 wherein the infection is a protozoa infection or bacterial infection and disorders related to such infections.
42. (New) The method according to Claim 41 wherein the infection or disorder is selected from the group consisting of pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Staphylococcus*

Application No.: 10/717,290

aureus, or *Peptostreptococcus* spp. *Pseudomonas* spp.; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by *Streptococcus pyogenes*, Groups C and G streptococci, *Clostridium diphtheriae*, or *Actinobacillus haemolyticum*; respiratory tract infections related to infection by *Mycoplasma pneumoniae*, *Legionella pneumophila*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, or *Chlamydia pneumoniae*; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by *Staphylococcus aureus*, coagulase-positive staphylococci, *S. pyogenes*, *S. agalactiae*, Streptococcal groups C-F, *viridans streptococci*, *Corynebacterium* spp., *Clostridium* spp., or *Bartonella henselae*; uncomplicated acute urinary tract infections related to infection by *S. saprophyticus* or *Enterococcus* spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by *Chlamydia trachomatis*, *Haemophilus ducreyi*, *Treponema pallidum*, *Ureaplasma urealyticum*, or *Nesseria gonorrhoeae*; toxin diseases related to infection by *S. aureus*, or Groups A, S. and C streptococci; ulcers related to infection by *Helicobacter pylori*; systemic febrile syndromes related to infection by *Borrelia recurrentis*; Lyme disease related to infection by *Borrelia burgdorferi*; conjunctivitis, keratitis, and dacrocystitis related to infection by *C. trachomatis*, *N. gonorrhoeae*, *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenzae*, or *Listeria* spp.; disseminated *Mycobacterium avium complex (MAC)* disease related to infection by *Mycobacterium avium*, or *Mycobacterium intracellulare*; gastroenteritis related to infection by *Campylobacter jejuni*; intestinal protozoa related to infection by *Cryptosporidium* spp. odontogenic infection related to infection by *viridans streptococci*; persistent cough related to infection by *Bordetella pertussis*; gas gangrene related to infection by *Clostridium perfringens* or *Bacteroides* spp.; Skin infection by *S. aureus*, *Propionibacterium acne*; atherosclerosis related to infection by *Helicobacter pylori* and *Chlamydia pneumoniae*.